Investment Considerations Kairos Pharma’s partnership with Cedars-Sinai Medical Center enhances clinical trial efficiency and accelerates the development of new therapeutic solutions. The company holds a robust intellectual property portfolio with patents extending through 2040, providing a strong competitive advantage in the oncology market. ENV105, Kairos’s lead drug candidate, shows promise in reversing drug resistance in … Continue reading “Kairos Pharma Ltd. (NYSE American: KAPA)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |